€3m grant for Nuritas

Irish biotechnology and R&D company Nuritas has unveiled details of a scientific breakthrough in the fight against the global diabetes epidemic.

The identification of a scientifically validated and patent filed peptide represents a major breakthrough in the battle to prevent type 2 diabetes. This natural ingredient, found within food, carries the potential to prevent pre-diabetic patients developing diabetes. Currently, there is no proven medical or other treatment that can be recommended for pre-diabetics to help prevent their progression into diabetes.

The EU’s Horizon 2020 funding will now unlock more than €3 million for Nuritas to support the final stage of its research and the commercialisation of the development. This will include a series of Irish based clinical trials being rolled out over the next 18 months. Pending regulatory approval, Nuritas will have its new peptide integrated into functional food products and available on the market as early as 2020.

Nuritas CEO Emmet Browne says, “This is a hugely important validation for Nuritas and our use of cutting edge artificial intelligence driven technology to transform the future of food and disease prevention around the globe. While we have a rich pipeline of similar breakthrough peptides, all found from natural sources with amazing scientific potential, diabetes prevention now becomes Nuritas’ first important area of focus, with many more to follow.

“This peptide carries huge potential to bridge an enormous gap in medical science and act as a major weapon in the global battle against diabetes, now recognised as a full blown epidemic.

“This is the essence of why Nuritas exists and we are delighted that after significant and deep consideration, the EU has demonstrated such faith in Nuritas’ ability to tackle this huge global issue.”